Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Kohlmeier-Degos Disease With Neurological Involvement
NCT06923072Phase 2Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Feb 2026
- Primary completion
- Dec 2030
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in malignant atrophic papulosis (MAP), sponsored by National Heart, Lung, and Blood Institute. Started Feb 2026; status: recruiting.
02
Drugs
baricitinib
03
Conditions
malignant atrophic papulosis (MAP)
Beyond the preview
Go deeper on NCT06923072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06923072.